NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, Price Target & More

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its quarterly earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.06. The biotechnology company had revenue of $69.16 million for the quarter, compared to analysts' expectations of $78.65 million. Ironwood Pharmaceuticals had a negative return on equity of 2,073.20% and a negative net margin of 34.12%. The business's quarterly revenue was up 32.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.33) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Ironwood Pharmaceuticals.

9 brokerages have issued twelve-month price targets for Ironwood Pharmaceuticals' stock. Their predictions range from $13.00 to $25.00. On average, they expect Ironwood Pharmaceuticals' share price to reach $19.4444 in the next year. This suggests that the stock has a possible downside of 6.0%. View Analyst Ratings for Ironwood Pharmaceuticals.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Ironwood Pharmaceuticals include Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY) and United Therapeutics (UTHR).

Media stories about IRWD stock have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ironwood Pharmaceuticals earned a coverage optimism score of 0.05 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 44.85 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Ironwood Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.14%) and V Wealth Management LLC (0.01%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

IRWD stock was acquired by a variety of institutional investors in the last quarter, including V Wealth Management LLC. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $20.68.

Ironwood Pharmaceuticals has a market capitalization of $3.20 billion and generates $298.28 million in revenue each year. The biotechnology company earns $-116,930,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Ironwood Pharmaceuticals employs 730 workers across the globe.

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]